Sofinnova Partners Announces New Investment In Nanophoria, Developer Of An Innovative Non-viral Drug Delivery Platform

Milan-based NanoPhoria raised €3.5 million in seed financing to advance its pre-clinical stage treatment for heart failureMILAN, ITALY / ACCESSWIRE / May 12, 2022 / Sofinnova Partners, a leading European

Related Keywords

Italy ,Milan ,Lombardia ,Paris ,France General ,France ,Berlin ,Germany ,London ,City Of ,United Kingdom ,Kostenloser Wertpapierhandel ,Lucia Faccio ,Michele Iafisco ,Alessio Alogna ,Daniele Catalucci ,Pierluigi Cavarai ,National Research Council ,Sofinnova Telethon Fund ,Technology For Ceramics ,Institute Of Genetic ,Institute Of Science ,Biomedical Research ,Milan Based Nanophoria ,Sofinnova Partners ,Research Director ,Senior Researcher ,Clinical Scientist ,Claudio De Luca ,Sofinnova Telethon ,Chief Scientific ,Sofinnova ,Partners ,Nnounces ,Investment ,Anophoria ,Developer ,Nnovative ,Viral ,Drug ,Delivery ,Platform ,